Clinical trial reportLung cancer (Amsterdam, Netherlands)Published
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Lung cancer (Amsterdam, Netherlands)
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Disease Progression; Carboplatin; Antineoplastic Combined Chemotherapy Protocols; Mutagenesis, Insertional; Mutation; Exons; Quality of Life; Adult; Aged
- PubMed ID
- 41671629
- Added to directory
- Source checked